Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Alumis (Nasdaq: ALMS) closed an upsized underwritten public offering on January 9, 2026, selling 20,297,500 shares of common stock at $17.00 per share, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares. The gross proceeds to Alumis were approximately $345.1 million before underwriting discounts, commissions and offering expenses. All offered shares were sold by Alumis under a shelf registration on Form S-3 declared effective on August 19, 2025. Joint book-running managers and co-lead managers were named for the transaction. The company noted prospectus documents are available on the SEC website and from the listed managers.
Positive
- Gross proceeds of approximately $345.1 million
- Offering fully subscribed with 2,647,500-share option exercise
- All shares sold by company, providing direct capital to Alumis
- Offering conducted under an SEC-declared Form S-3 shelf registration effective Aug 19, 2025
Negative
- Issuance of 20,297,500 new shares is dilutive to existing shareholders
- Net proceeds will be reduced by underwriting discounts, commissions and offering expenses
News Market Reaction – ALMS
In the Jan 12 session, ALMS gained 7.82%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.5% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Offering priced | Negative | +10.4% | Upsized underwritten offering priced at $17 with ~$300M gross proceeds. |
| Jan 06 | Offering proposed | Negative | +95.3% | Proposed $175M common stock offering with option for additional $26.25M. |
| Jan 06 | Phase 3 results | Positive | +95.3% | Positive Phase 3 envudeucitinib data showing strong PASI and sPGA responses. |
| Jan 05 | Conference call | Neutral | -7.2% | Announcement of webcast to discuss ONWARD topline Phase 3 data. |
| Nov 13 | Earnings update | Neutral | +0.8% | Q3 2025 financials with $377.7M liquidity and net loss of $110.8M. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows strong positive reactions to clinical and early offering announcements, with mixed alignment around informational events like conference calls. Offering-related headlines have previously seen sharp positive moves despite potential dilution.
Over the last few months, Alumis reported Q3 2025 results on Nov 13, 2025, highlighting $377.7 million in cash, cash equivalents and marketable securities and a net loss of $110.8 million. In early January 2026, the company built on positive Phase 3 psoriasis data by announcing a proposed offering on Jan 6 and then pricing an upsized deal on Jan 7, both under an effective shelf registration. Those financing steps generated strong share price reactions, framing today’s closing announcement as the completion of that capital-raising sequence.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
base prospectus regulatory
securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of
Morgan Stanley, Leerink Partners, Cantor and Wells Fargo Securities acted as joint book-running managers for the offering. Baird and Oppenheimer & Co. acted as co-lead managers for the offering.
The public offering was made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on August 19, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649, or by email at prospectus@morganstanley.com; Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com; or Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, at 800-645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Alumis
Alumis is a clinical-stage biopharmaceutical company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib (or envu, formerly known as ESK-001) for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Alumis Contact Information Teri Dahlman Red House Communications teri@redhousecomms.com